S&P 500   2,996.07 (-0.35%)
DOW   26,788.51 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.33 (-3.92%)
MSFT   136.39 (-1.47%)
GOOGL   1,241.75 (-0.20%)
AMZN   1,765.86 (-1.11%)
CGC   21.10 (+3.69%)
NVDA   195.91 (-0.05%)
MU   44.66 (-1.24%)
BABA   169.81 (-2.14%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.18 (-0.13%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.77 (+0.06%)
NFLX   266.69 (-4.09%)
BAC   31.18 (+0.52%)
GILD   65.88 (+1.03%)
DIS   132.41 (+1.65%)
S&P 500   2,996.07 (-0.35%)
DOW   26,788.51 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.33 (-3.92%)
MSFT   136.39 (-1.47%)
GOOGL   1,241.75 (-0.20%)
AMZN   1,765.86 (-1.11%)
CGC   21.10 (+3.69%)
NVDA   195.91 (-0.05%)
MU   44.66 (-1.24%)
BABA   169.81 (-2.14%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.18 (-0.13%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.77 (+0.06%)
NFLX   266.69 (-4.09%)
BAC   31.18 (+0.52%)
GILD   65.88 (+1.03%)
DIS   132.41 (+1.65%)
Log in

Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

$38.95
+2.45 (+6.71 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$36.99
Now: $38.95
$39.20
50-Day Range
$26.96
MA: $31.02
$36.59
52-Week Range
$10.41
Now: $38.95
$38.75
Volume82,009 shs
Average Volume1.34 million shs
Market Capitalization$3.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.14 million
Book Value$1.08 per share

Profitability

Net Income$-54,450,000.00

Miscellaneous

Employees116
Market Cap$3.69 billion
Next Earnings Date12/10/2019 (Estimated)
OptionableOptionable

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings data on Monday, August, 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.34 by $0.13. The biotechnology company had revenue of $42.70 million for the quarter, compared to the consensus estimate of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December 10th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

5 equities research analysts have issued 1 year price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $24.00 to $54.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $41.60 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Headlines about ARWR stock have trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a news impact score of -4.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Arrowhead Pharmaceuticals.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), Sasol (SSL), Sarepta Therapeutics (SRPT), Alliance Resource Partners (ARLP), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Omeros (OMER) and Exelixis (EXEL).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bailard Inc. (0.11%), State of Alaska Department of Revenue (0.08%), Strs Ohio (0.04%), Brinker Capital Inc. (0.04%), Envestnet Asset Management Inc. (0.04%) and Vanguard Capital Wealth Advisors (0.02%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Bailard Inc., Meeder Asset Management Inc. and Vanguard Capital Wealth Advisors. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Pacer Advisors Inc., Strs Ohio, Calamos Advisors LLC, Arden Trust Co, Brinker Capital Inc., Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $38.82.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $3.68 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel